Table 1.
Characteristics of the patients.
| Characteristics, N (%) | irAE Group (n=70) | Non-irAE Group (n=121) | P | |
|---|---|---|---|---|
| Sex | Male | 54 (38.8) | 85 (61.2) | 0.302 |
| Female | 16 (30.8) | 36 (69.2) | ||
| Age (years) | <65 | 52 (41.9) | 72 (58.1) | 0.039 |
| ≥65 | 18 (26.9) | 49 (73.1) | ||
| NSCLC histology | Adenocarcinoma | 41 (38.0) | 67 (62.0) | 0.497 |
| Squamous carcinoma | 27 (37.5) | 45 (62.5) | ||
| Others | 2 (18.2) | 9 (81.8) | ||
| ECOG | 0–1 | 68 (38.2) | 110 (61.8) | 0.138 |
| ≥2 | 2 (15.4) | 11 (84.6) | ||
| Changes in weight before treatment | No change | 55 (37.4) | 92 (62.6) | 0.688 |
| Loss of weight | 15 (34.1) | 29 (65.9) | ||
| Smoking history | Yes | 27 (38.0) | 44 (62.0) | 0.945 |
| No | 42 (36.2) | 74 (63.8) | ||
| Unknown | 1 (25.0) | 3 (75.0) | ||
| Stage | I | 1 (20.0) | 4 (80.0) | 0.675 |
| II | 4 (25.0) | 12 (75.0) | ||
| III | 17 (34.0) | 33 (66.0) | ||
| IV | 47 (39.8) | 71 (60.2) | ||
| Unknown | 1(50) | 1 (50) | ||
| EGFR status | Wild type | 46 (38.7) | 73 (61.3) | 0.746 |
| Mutant | 5 (31.3) | 11 (68.8) | ||
| Unknown | 19 (33.9) | 37 (66.1) | ||
| ALK status | Wild type | 55 (38.7) | 87 (61.3) | 0.614 |
| Fusion | 0 (0) | 1 (100.0) | ||
| Unknown | 15 (31.3) | 33 (68.8) | ||
| Lines of immunotherapy | First line | 39 (52.0) | 36 (48.0) | 0.005 |
| Second line | 15 (27.3) | 40 (72.7) | ||
| Third line and above | 11 (24.4) | 34 (75.6) | ||
| Others | 5 (31.3) | 11 (68.7) | ||
| Type of drug | Anti-PD-1 | 43 (27.9) | 111 (72.1) | <0.001 |
| Anti-PD-L1 | 27 (73.0) | 10 (27.0) | ||
| Therapeutic modalities | Single drug | 29 (29.3) | 70 (70.7) | 0.019 |
| Combined with chemotherapy | 35 (42.7) | 47 (57.3) | ||
| Combined with CTLA-4 | 5 (83.3) | 1 (16.7) | ||
| Others | 1 (25.0) | 3 (75.0) | ||
irAE, immune-related adverse events; NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; EGFR, epithelial growth factor receptor; ALK, anaplastic lymphoma kinase; PD-1, programmed cell death protein 1; PD-L1, programmed cell death protein ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4. P-values <0.05 were considered statistically significant.